Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 688 results
Found 688 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

C

Okusanya O, Forrest A, DiFrancesco R, et al. "Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks." Antimicrob. Agents Chemother.. 2007;51(5):1822-6.
Day JR, Martínez LE, Sásik R, et al. "A computer-based, image-analysis method to quantify HIV-1 infection in a single-cycle infectious center assay." J. Virol. Methods. 2006;137(1):125-33.
Shivakoti R, Yang W-T, Gupte N, et al. "Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy Initiation." Clin. Infect. Dis.. 2015;61(1):102-10.
Balagopal A, Gupte N, Shivakoti R, et al. "Continued Elevation of Interleukin-18 and Interferon-γ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort." Open Forum Infect Dis. 2016;3(3):ofw118.
Riddler SA, Aga E, Bosch RJ, et al. "Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy." J. Infect. Dis.. 2016;213(4):556-60.
Bosch RJ, Pollard RB, Landay A, Aga E, Fox L, Mitsuyasu R. "Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)." AIDS Res Ther. 2010;7:30.
Vogler MA, Patterson K, Kamemoto L, et al. "Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188." J. Acquir. Immune Defic. Syndr.. 2010;55(4):473-82.
Godfrey C, Villa C, Dawson L, Swindells S, Schouten JT. "Controlling healthcare-associated infections in the international research setting." J. Acquir. Immune Defic. Syndr.. 2013;62(4):e115-8.
Melvin AJ, Kang M, Hitti J, et al. "Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy." Antivir. Ther. (Lond.). 2008;13(3):349-55.
Zhou L, Kitch DW, Evans SR, et al. "Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy." Neurology. 2007;68(24):2113-9.
Carlson JM, Brumme CJ, Martin E, et al. "Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1." J. Virol.. 2012;86(24):13202-16.
Girouard MP, Sax PE, Parker RA, et al. "The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States." Clin. Infect. Dis.. 2016;62(6):784-91.
Morris BL, Scott CA, Wilkin TJ, et al. "Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development." HIV Clin Trials. 2012;13(1):1-10.
Schackman BR, Haas DW, Park SS, X Li C, Freedberg KA. "Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice." Pharmacogenomics. 2015;16(18):2007-18.
Tenforde MW, Gupte N, Dowdy DW, et al. "C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings." PLoS ONE. 2015;10(2):e0117424.
Lederman MM, Smeaton L, Smith KY, et al. "Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138." J. Infect. Dis.. 2006;194(12):1677-85.
Gupta SK, Kitch D, Tierney C, et al. "Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial." Open Forum Infect Dis. 2014;1(1):ofu003.
Freeman ML, Shive CL, Nguyen TP, Younes S-A, Panigrahi S, Lederman MM. "Cytokines and T-Cell Homeostasis in HIV Infection." J. Infect. Dis.. 2016;214 Suppl 2:S51-7.
Weinberg A, Tierney C, Kendall MA, et al. "Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy." J. Infect. Dis.. 2006;193(4):488-93.

D

Tenorio AR, Jiang H, Zheng Y, et al. "Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115." AIDS Res. Hum. Retroviruses. 2009;25(2):135-9.
Cohn SE, Park J-G, Watts DH, et al. "Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions." Clin. Pharmacol. Ther.. 2007;81(2):222-7.
Luque AE, Cohn SE, Park J-G, et al. "Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the." Antimicrob. Agents Chemother.. 2015;59(4):2094-101.
Demeter LM, A Mukherjee L, DiFrancesco R, et al. "The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients." HIV Clin Trials. 2008;9(1):61-72.
Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM. "Design issues in initial HIV-treatment trials: focus on ACTG A5095." Antivir. Ther. (Lond.). 2006;11(6):751-60.
Zheng L, Rosenkranz SL, Taiwo B, Para MF, Eron JJ, Hughes MD. "The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients." AIDS Res. Hum. Retroviruses. 2013;29(4):652-7.
Seaman WT, Andrews E, Couch M, et al. "Detection and quantitation of HPV in genital and oral tissues and fluids by real time PCR." Virol. J.. 2010;7:194.
C Hare B, Mellors J, Krambrink A, et al. "Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy." Clin. Infect. Dis.. 2008;47(3):421-4.
Goicoechea M, Smith DM, Liu L, et al. "Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA." J. Infect. Dis.. 2006;194(1):29-37.
Firnhaber C, Smeaton LM, Grinsztejn B, et al. "Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial." HIV Clin Trials. 2015;16(3):89-99.
Chan ES, Landay AL, Brown TT, et al. "Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir." AIDS. 2016;30(13):2091-7.

Pages